Peking University Resources (Holdings) Company Limited Overview
Peking University Resources is a small-cap, Bermuda-domiciled, Hong Kong-listed holding company. It is part-way through a deliberate exit from Chinese residential property development, which was its dominant business from 2013 to 2024. That business collapsed under default litigation, guarantee claims and the 2020 bankruptcy reorganisation of its former parent, Peking University Founder Group. In August 2025 the company placed its last property-development subsidiaries into an off-balance-sheet partnership. This deconsolidated defaulted loans and guarantee provisions and produced a one-off RMB1.65 billion profit in FY2026. What remains is a sub-scale portfolio of four activities: an e-commerce brand-operation and distribution business (60% of FY2026 revenue); the "Ye Kai Tai" traditional-Chinese-medicine pharmacy chain in Wuhan; a run-off property-leasing book; and an SFC-licensed special-situations asset-management subsidiary. In July 2026 the company also announced two acquisitions in Tanzania (aluminium extrusion and lead-battery recycling). The equity case rests on whether management can turn a cleaned-up balance sheet into recurring operating profit. So far it has not.
Company's own description (FY2026 Annual Report, Company Profile)
The FY2026 annual report says the Group is principally engaged in four activities in Mainland China, Singapore and Hong Kong:
-
medical and pharmaceutical retail;
-
e-commerce and distribution;
-
property development;
-
property investment and management.
As at 31 March 2026 the pharmacies, which trade under the "Yekaitai (葉開泰)" brand, comprised:
-
38 retail pharmacies;
-
15 TCM clinics;
-
1 beauty clinic;
-
1 dermatology clinic;
-
an online pharmacy.
The e-commerce and distribution business sells consumer electronics, health food and other products through Douyin, JD.com and other distributors. The property investment business leases unsold completed properties. Through a subsidiary holding an SFC Type 9 (asset management) licence, the Group also runs a special-opportunities asset-management business.
Independent characterisation
Economically, the group is now three things:
-
A low-margin e-commerce "TP" operator and distributor. It is a brand partner and channel operator for domestic brands such as Joyoung, Huawei, Xiaomi, Jinlongyu and Aodong. It runs stores and content campaigns across JD.com, Tmall/Taobao, Pinduoduo, Vipshop, Douyin, Xiaohongshu, Kuaishou and WeChat Channels.
-
Revenue is recognised mostly on a gross basis from product sales.
-
Segment profit margin was 3.2% in FY2026, which is consistent with distribution rather than fee-based TP economics.
-
This business descends from the group's legacy IT-products distribution arm (EC-Founder heritage). That arm was largely dismantled in FY2023–FY2024 after litigation from Peking Founder and a creditor.
-
-
A regional TCM-oriented pharmacy chain. Ye Kai Tai is a roughly 400-year-old Wuhan brand recognised as a "China Time-honored Brand" (中華老字號) in 1994. It was acquired in two steps (August and November 2023) for a total of RMB81m. The chain is shrinking: 56 stores at March 2024, 47 at March 2025 and 38 at March 2026. It lost RMB54.7m in FY2026, including a RMB38.6m goodwill impairment.
-
A property run-off and special-situations vehicle.
-
About 284,300 sqm of completed properties remained held for sale at 31 March 2026.
-
Investment properties are still being sold down.
-
The Type 9 licensed subsidiary has so far mainly managed vehicles tied to the group's own distressed property assets, including the partnership that absorbed the property-development subsidiaries.
-
Revenue model mix (FY2026)
| Revenue type | Segment | FY2026 revenue (CNY Mn) | Share of group (%) | Model |
|---|---|---|---|---|
| Product sales (gross) | E-commerce and distribution | 936.1 | 60.3 | Transactional / distribution |
| Pharmaceutical retail plus medical/consultation services | Medical and pharmaceutical retail | 155.1 | 10.0 | Retail plus service fees |
| Property sales (delivery-based) | Property development | 377.3 | 24.3 | One-off, non-recurring (run-off) |
| Rental and property management fees | Property investment and management | 83.0 | 5.3 | Recurring lease (shrinking) |
| Total | — | 1,551.5 | 100.0 | — |
There is no subscription or licensing revenue. Asset-management fee income is not separately disclosed and appears immaterial.
Value-chain position, customers and end-markets
| Segment | Value-chain position | Customer type | End-market |
|---|---|---|---|
| E-commerce and distribution | Mid-stream brand operator / distributor between manufacturers and platforms | Consumers (B2C via platforms) and distributors (B2B) | China online retail: consumer electronics, small appliances, health food |
| Pharma retail | Downstream retail and primary TCM care | Retail patients, medical-insurance-settled purchases | China retail pharmacy and TCM services (Wuhan focus); Singapore (minor); Dubai (ResoHealth, early stage) |
| Property development | Developer (now run-off) | Homebuyers | China residential (Tier-2/3 cities) |
| Property investment | Landlord / property manager | Commercial tenants | China commercial leasing |
| Asset management | Special-situations GP / manager | Institutional LPs (partners in group-related vehicles) | China real-estate NPAs; stated interest in healthcare and technology |
Strategy
Stated strategic themes (FY2026 Chairman's Statement and MD&A)
-
The company describes a completed "key strategic realignment": the August 2025 partnership "effectively eliminating historical risks" and leaving the group with no property projects under development.
-
The guiding philosophy is "prudent operations and innovative development", aligned with the national 15th Five-Year Plan (2026–2030) on the digital economy and healthcare.
E-commerce: refine the omnichannel system, deepen digitalisation, upgrade the supply chain, explore cross-border e-commerce, and build a dual engine of "e-commerce operations + health products", including possible own-brand health products.
Pharma: accelerate the "pharmacies + TCM consultations + digital health" model; integrate medical resources and specialised clinics; pursue AI-enabled service; expand digital healthcare globally (Dubai).
Property: orderly leasing and disposal of completed assets to generate cash for the core businesses.
Asset management: prudently develop special-opportunity asset investment, including in technology-related industries.
Initiatives announced in the last 24 months (October 2024 to October 2026)
| Date | Initiative | Type | Status |
|---|---|---|---|
| 7 May 2025 | Partnership with Suzhou Aoze and Chongqing Jingjiahui; injection of On Tai group | Restructuring / deleveraging | Completed 11 Aug 2025 |
| FY2026 | Store rationalisation; new Wuhan TCM clinic + pharmacy complex | Operational | Ongoing (38 stores) |
| Oct 2025 | "Ye Kai Tai Health" AI app | Digital platform | Launched |
| FY2026 | ResoHealth FZCO, Dubai; LetsGo digital-health platform | New business / geographic expansion | Early stage |
| 9 Jan 2026 | Trivitron Digital AI digital-health programme with Trivitron Healthcare | Partnership | Announced |
| 30 Mar 2026 | JV with Shanghai Cun'an and Mr Feng for non-ferrous metals international trade and supply chain | New business | Terminated 29 Jul 2026 before capital injection |
| 29 Jul 2026 | Acquisition of Tanzanian aluminium extruder and lead-battery recycler (US$6.59m) | Diversification M&A | Pending (registration within 3 months) |
| FY2025–FY2026 | Disposal of residual property-investment entities (Hangzhou Linghangxing, Chongqing Yuefeng, Tianjin Ruihesheng) | Portfolio clean-up | Completed |
Cost programmes and targets
-
Selling, distribution and administrative expenses fell 27% in FY2026 to RMB259.5m, attributed to deconsolidation and streamlining.
-
Headcount fell from 735 to 512.
-
No quantified cost-saving targets have been published.
Medium-term financial targets and guidance
None published. The company provides no revenue, margin or return guidance. Its only forward-looking financial communication in the period was the 17 June 2026 positive profit alert (RMB1.4–1.8bn profit for FY2026), which the actual result of RMB1.645bn fell within.
Analyst view on strategic coherence. The last 24 months show a pattern of opportunistic, loosely connected initiatives: AI health apps, a Dubai health subsidiary, an Indian medtech partnership, a metals-trading JV abandoned within four months, and East African aluminium and lead-battery assets. None is clearly related to the stated e-commerce and TCM core, and none comes with disclosed capital budgets or return targets. This is the main strategic weakness after the balance-sheet clean-up.
Products & Services
Medical and pharmaceutical retail
| Offering | Description / capabilities | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Ye Kai Tai retail pharmacies | 38 stores (31 Mar 2026), down from 47 (Mar 2025) and 56 (Mar 2024); Wuhan-centred; OTC, prescription and TCM products | Wuhan residents; medical-insurance-settled buyers | Brand history approx. 400 years; acquired 2023 | Retail margin |
| Ye Kai Tai TCM clinics | 15 clinics (Mar 2026), up from 11 (Mar 2025) and 5 (Mar 2024); TCM diagnosis, acupuncture, massage, physiotherapy, herbal prescriptions | Chronic-condition and wellness patients | Expansion since Aug 2023 under the "pharmacy + TCM" model | Consultation fees plus herbal/drug sales |
| TCM clinic + pharmacy complex (Wuhan) | New flagship-format integrated outlet | Same | Added FY2026 | Same |
| Beauty clinic | 1 clinic | Aesthetic consumers | Disclosed FY2026 | Service fees |
| Dermatology clinic | 1 clinic | Dermatology patients | Disclosed FY2026 | Service fees |
| Online pharmacy (B2C) and O2O instant delivery | Platform-based online drug retail and instant delivery | Online consumers | Expanded FY2025–FY2026 | Retail margin |
| "Ye Kai Tai Health" app | AI and big-data platform: intelligent consultation, syndrome differentiation and medication recommendation, health management, drug delivery; membership and WeChat private-traffic operations | Members / repeat customers | Launched Oct 2025 | — |
| ResoHealth FZCO / LetsGo platform (Dubai) | AI-driven corporate health management: prevention, screening, management, intervention | Employers, insurers, medical institutions in Dubai and the Middle East | Established FY2026 | — |
| Trivitron Digital AI programme | Digital-health programme launched with Trivitron Healthcare (voluntary announcement 9 Jan 2026) | — | Jan 2026 | — |
| Singapore operations | Small pharma/medical revenue (RMB9.1m in FY2024) | Singapore customers | FY2024 | — |
E-commerce and distribution
| Offering | Description | Partner brands / platforms | Pricing model |
|---|---|---|---|
| Brand self-operation | Group-operated online stores selling partner-brand goods | Joyoung, Huawei, Xiaomi, Jinlongyu, Aodong | Product margin |
| Channel distribution | Wholesale to platform self-operated channels and distributors | JD.com, Vipshop, others | Distribution margin |
| Platform cooperation / content commerce | Content marketing and live-stream on Douyin, Xiaohongshu, Kuaishou, WeChat Channels; cross-platform conversion paths (e.g., Xiaohongshu content to JD/Tmall conversion; Douyin live-stream to JD/Tmall repurchase) | Same brands | Product margin (fee components not disclosed) |
| One-stop brand services | Front-end brand positioning, visual identity and packaging design; mid-end store operations and campaigns; back-end 24/7 customer service | Brand clients | — |
| Health products (planned) | Health food, health-care products, medical aids; possible own-brand health products "at the appropriate time" | Planned | Not yet launched |
| Cross-border e-commerce (planned) | Stated exploration in the FY2026 Chairman's Statement | Planned | Not yet launched |
Property
| Offering | Status at 31 Mar 2026 |
|---|---|
| Completed residential/commercial units held for sale | Approx. 284,300 sqm. FY2026 contracted sales RMB420m on 85,000 sqm (approx. RMB5,085/sqm). |
| Investment properties (leasing) | Leasable area reduced by the On Tai disposal and asset sales. FY2026 fair-value loss RMB206.6m. |
| Property management services | Revenue RMB17.7m in FY2024; later years not separately retrieved. |
| Project | Location | Use | Planned GFA (sqm) | Equity share | Status (Mar 2024) |
|---|---|---|---|---|---|
| Yihe Emerald Mansion | Yuxi, Yunnan | Residential/Commercial | 456,507 | 100% | Expected 2026 |
| Boya Binjiang | Foshan, Guangdong | Residential/Commercial | 909,598 | 51% | Expected 2024 |
| Wei Ming 1898 | Kaifeng, Henan | Residential/Commercial | 384,569 | 100% | Expected 2024 |
| Zijing Mansion | Chongqing | Residential/Commercial | 209,632 | 100% | Completed |
| Boya | Chongqing | Residential/Commercial | 499,947 | 70% | Completed |
| Jiangshan Mingmen | Chongqing | Residential/Commercial | 706,601 | 100% | Completed |
| Yuelai | Chongqing | Residential/Commercial | 425,947 | 70% | Completed |
| Boya City Plaza | Chengdu, Sichuan | Commercial/Office | 144,008 | 51% | Completed |
| Wei Ming Mansion | Hangzhou, Zhejiang | Residential/Commercial | 193,736 | 100% | Completed |
| Shanshui Nianhua | Wuhan, Hubei | Residential/Commercial | 278,437 | 70% | Completed |
| 580 Project | Chongqing | Residential/Commercial | 613,530 | 100% | Not commenced |
| Lianhu Jincheng | Ezhou, Hubei | Residential/Commercial | 394,175 | 90% | Not commenced (Ezhou Jinfeng sold May 2024) |
Legacy project list at 31 March 2024 (12 projects in 8 cities):
The Yuxi, Kaifeng, Chongqing (several), Hangzhou (Zhejiang Resources) and Wuhan (Tianhe Jincheng) entities were among the 16 On Tai subsidiaries injected into the partnership in August 2025. A project-level list of what remains after the disposal was not published in the material retrieved.
Asset management
| Offering | Detail |
|---|---|
| SFC Type 9 licensed manager | Peking University Resources Asset Management Ltd (licence April 2023) |
| Hong Kong Gateway / Stock Connect Special Opportunities Return LP Fund | Investment manager since Dec 2023 |
| Suzhou Aoze JV (8 Aug 2024) | Real-estate and healthcare NPA investment |
| Suzhou Aoze partnership (7 May 2025) | Debt restructuring and development of the group's former property projects; group is subordinated LP |
Pending new businesses (announced 29 July 2026)
| Target | Business | Consideration | Reported net assets (end-2025) |
|---|---|---|---|
| LN Future Building Materials Co. Ltd (Tanzania), 100% | Major East African aluminium-profile manufacturer: casting, extrusion, surface treatment, QC | US$4.17m | Approx. RMB283m |
| China Boda Technical Group Ltd (Tanzania), 99% | Waste-battery recycling, recycled lead, lead-acid battery production and sale | US$2.42m | Approx. RMB165m |
Financial Narrative
Sources and conventions:
-
Sources: company annual reports and results announcements for FY2023 (AR 2022/23), FY2024 (results announcement 28 Jun 2024), FY2025 (results 30 Jun 2025) and FY2026 (AR 2025/26). FY2022 figures come from the FY2023 annual report comparatives.
-
FY2022 is 15 months.
-
Rows marked "aggregator" come from stockanalysis.com and use that site's definitions.
Income statement
Notes on the income statement:
-
Pre-tax profit for FY2022, FY2025 and FY2026 is derived as net profit plus tax.
-
FY2025 "other gains" (RMB327m) and selling/admin expenses come from the Reuters/PUBT summary of the FY2025 results.
-
FY2024 adjusted to the post-consolidation share count would be about -32.96 RMB cents (analyst adjustment).
-
Data conflicts:
-
The aggregator shows FY2022 revenue of RMB9,440m and net income of RMB1,208m. The annual report shows RMB11,799.6m and RMB1,509.5m (15 months). The aggregator appears to use a different period basis. The filing figures are used here.
-
FY2026 gross profit is RMB115.1m in the MD&A versus RMB88.7m on the aggregator.
-
FY2025 gross loss is RMB53.0m in the MD&A versus RMB60.5m on the aggregator.
-
Margins and growth (%)
Revenue CAGR FY2023–FY2026 (three 12-month years) is -33.1% a year (RMB5,174.9m to RMB1,551.5m). A five-year CAGR is not meaningful because FY2022 is a 15-month period.
Trend commentary. Group revenue has fallen 87% from the 15-month FY2022 peak. This reflects three things: the forced unwinding of the IT distribution business after litigation by Peking Founder and a creditor; the run-down of property deliveries; and the deconsolidation of subsidiaries.
The bottom line has swung between large profits and large losses almost entirely on non-operating items:
-
disposal gains (RMB3.9bn in FY2022, RMB1.2bn in FY2024, RMB2.16bn in FY2026);
-
guarantee and litigation provisions (RMB744m in FY2024 and about RMB1.6bn of other losses in FY2025);
-
land resumption losses (RMB336.6m in FY2024);
-
property impairments and fair-value moves.
On the aggregator's operating-income definition, which excludes these items, the group has made an operating loss in every year shown. The operating loss in FY2026 was RMB184.5m, an 11.9% negative margin. This is the crucial point: the FY2026 headline profit is an accounting consequence of deconsolidation, not evidence of earnings power.
Balance sheet
Notes on the balance sheet:
-
FY2025 equity attributable to owners was a deficit.
-
FY2025 and FY2026 net current assets are not quantified in retrieved text. The current ratios of 0.88 and 1.33 imply negative and positive working capital respectively.
-
Goodwill relating to pharma (RMB38.6m) was impaired in FY2026, implying that pharma goodwill is now nil or near nil.
-
Data conflict on FY2023 borrowings: the FY2023 Annual Report shows RMB1,919.6m (RMB1,325.9m current). The comparative restated in the FY2024 results shows RMB2,339.6m (RMB1,745.9m current, RMB593.7m non-current). The annual-report figure is used above. The restated figure implies FY2023 net debt of RMB1,613.7m.
-
NAV per share: the FY2026 AR reports 64.85 RMB cents (total equity including NCI divided by shares). On owners' equity, NAV per share is about 21.5 RMB cents, consistent with etnet's RMB0.215.
Cash flow
Notes:
-
Cash and restricted cash fell RMB354.6m in FY2026, partly from deconsolidation of the On Tai group's cash.
-
Capex for FY2024 is also given by the company as RMB11.8m (additions to PP&E and investment properties).
-
No buybacks were disclosed in any year.
Cash commentary. The group has burned operating cash in every year for which data is available, despite large working-capital releases from property inventory (inventory change of RMB2.6bn in FY2022 and RMB0.6bn in FY2025 per the aggregator). Equity raises have been tiny: HK$34.2m from the May 2024 subscription, plus option exercises. Liquidity has instead come from asset disposals, debt-for-equity settlements and deconsolidations.
Ratios
Notes:
-
ROE on owners' equity is not meaningful because owners' equity was negative at end-FY2022 and end-FY2025.
-
Interest coverage includes one-off gains and losses and is distorted.
-
ROIC is not meaningful given negative operating income in every year.
-
Net debt/EBITDA is not meaningful because EBITDA was negative in FY2024–FY2026. In FY2026 the group was in net cash of RMB177.4m.
-
Cash conversion cycle components (receivable, inventory and payable days) were not disclosed in retrieved material. In FY2024, trade receivables were RMB224.6m and trade payables RMB1,285.6m, with 61% of payables aged over six months, which signals stretched payables in the property business.
Inflection assessment.
-
FY2026 is the cleanest balance sheet since at least FY2022: gearing of 0.07x, a current ratio of 1.33x, no mortgage guarantees and no PUD commitments.
-
But the asset base has shrunk by 79% since FY2022 (to RMB3.85bn), owners' equity is only RMB589.7m, and NCI (RMB1.19bn) still exceeds owners' equity.
-
Total liabilities of RMB2.07bn include RMB979.7m of other payables and accruals. The September 2026 Supreme People's Court judgment adds a fresh liability of about RMB187m plus interest since December 2019.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key entities / brands |
|---|---|---|
Medical and pharmaceutical retail | Chinese medicine, pharmaceutical retail, TCM consultation, beauty and dermatology clinics, online pharmacy, O2O delivery | Wuhan Yekaitai Pharmaceutical Chain Co., Ltd.; Ye Kai Tai Health app; ResoHealth FZCO (Dubai) |
E-commerce and distribution | Online sale of appliances, consumer electronics and health food; distribution | Partner brands Joyoung, Huawei, Xiaomi, Jinlongyu, Aodong |
Property development | Sale of residential and commercial units (run-off since Aug 2025) | Remaining completed inventory (approx. 284,300 sqm held for sale) |
Property investment and management | Leasing of retained properties; property management services | — |
Revenue by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Medical and pharmaceutical retail revenue (CNY Mn) | 0 | 0 | 87.8 | 190.8 | 155.1 |
E-commerce and distribution revenue (CNY Mn) | 7,371.0 | 1,907.2 | 621.4 | 711.9 | 936.1 |
Property development revenue (CNY Mn) | 4,332.8 | 3,219.7 | 558.2 | 605.2 | 377.3 |
Property investment and management revenue (CNY Mn) | 95.8 | 47.9 | 173.6 | 110.7 | 83.0 |
Total revenue (CNY Mn) | 11,799.6 | 5,174.9 | 1,441.0 | 1,618.5 | 1,551.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Medical and pharmaceutical retail result (CNY Mn) | 0 | 0 | 3.8 | -0.1 | -54.7 |
E-commerce and distribution result (CNY Mn) | 40.2 | -55.4 | 30.8 | 13.5 | 29.6 |
Property development result (CNY Mn) | 1,078.0 | 1,851.9 | -117.3 | -2,184.3 | 2,211.8 |
Property investment and management result (CNY Mn) | -335.0 | 85.0 | -29.8 | -133.0 | -440.6 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
E-commerce segment margin (%) | 5.0 | 1.9 | 3.2 |
Pharma segment margin (%) | 4.3 | -0.1 | -35.3 |
E-commerce revenue YoY growth (%) | -67.4 | 14.6 | 31.5 |
Pharma revenue YoY growth (%) | 0 | 117.3 | -18.7 |
Property development revenue YoY growth (%) | -82.7 | 8.4 | -37.7 |
Property investment revenue YoY growth (%) | 262.4 | -36.2 | -25.0 |
E-commerce share of revenue (%) | 43.1 | 44.0 | 60.3 |
Pharma share of revenue (%) | 6.1 | 11.8 | 10.0 |
Property development share of revenue (%) | 38.7 | 37.4 | 24.3 |
Property investment share of revenue (%) | 12.0 | 6.8 | 5.3 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 11,799.6 | 5,174.9 | 1,441.0 | 1,618.5 | 1,551.5 |
Gross profit (CNY Mn) | 1,154.4 | 760.8 | 130.8 | -53.0 | 115.1 |
Other gains and losses net (CNY Mn) | 5,775.6 | 1,992.7 | 515.9 | 327.0 | — |
Gains on disposal of subsidiaries (CNY Mn) | 3,928.6 | 306.5 | 1,202.7 | — | 2,163.3 |
Selling and administrative expenses (CNY Mn) | 743.9 | 314.3 | 234.7 | 355.4 | 259.5 |
Other expenses and losses (CNY Mn) | 1,578.9 | 647.0 | 842.7 | 1,614.2 | 173.9 |
Finance costs (CNY Mn) | 548.5 | 266.5 | 112.4 | 126.7 | 78.5 |
Operating income aggregator (CNY Mn) | -17.3 | -2.2 | -459.4 | -2,156.0 | -184.5 |
EBITDA aggregator (CNY Mn) | — | 2.6 | -454.1 | -2,149.1 | -176.6 |
Pre-tax profit (CNY Mn) | 241.6 | 1,596.5 | -742.8 | -2,456.5 | 1,643.8 |
Income tax expense (CNY Mn) | 675.3 | 577.7 | 7.5 | 63.1 | -1.2 |
Net profit total (CNY Mn) | -433.7 | 1,018.9 | -750.2 | -2,519.6 | 1,645.0 |
Net profit to owners (CNY Mn) | 1,509.5 | 966.7 | -785.6 | -2,339.9 | 1,783.5 |
Non-controlling interests (CNY Mn) | -1,943.2 | 52.2 | 35.4 | -179.7 | -138.5 |
Basic EPS as reported (MYR Bn cents) | 23.53 | 13.71 | -8.24 | -85.99 | 65.15 |
Diluted EPS as reported (MYR Bn cents) | 23.53 | 13.71 | -8.24 | -85.99 | 65.15 |
Dividend per share (MYR Bn cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 9.8 | 14.7 | 9.1 | -3.3 | 7.4 |
Operating margin aggregator (%) | -0.2 | 0.0 | -31.9 | -133.2 | -11.9 |
EBITDA margin aggregator (%) | — | 0.1 | -31.5 | -132.7 | -11.4 |
Net margin total profit (%) | -3.7 | 19.7 | -52.1 | -155.7 | 106.0 |
Revenue growth YoY (%) | — | -56.1 | -72.2 | 12.3 | -4.1 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 18,267.4 | 12,648.6 | 11,522.9 | 10,212.8 | 3,849.4 |
Total liabilities (CNY Mn) | 15,878.9 | 10,113.1 | 9,015.2 | 9,815.7 | 2,074.2 |
Total equity (CNY Mn) | 2,388.5 | 2,535.6 | 2,507.7 | 397.1 | 1,775.2 |
Equity attributable to owners (CNY Mn) | -462.1 | 1,461.5 | 1,034.5 | -1,256.2 | 589.7 |
Non-controlling interests (CNY Mn) | 2,850.6 | 1,074.1 | 1,473.2 | 1,653.3 | 1,185.5 |
Cash and restricted cash (CNY Mn) | 683.9 | 725.9 | 904.1 | 661.1 | 306.5 |
Total borrowings (CNY Mn) | 4,518.0 | 1,919.6 | 1,748.1 | 1,767.3 | 129.1 |
Borrowings due within one year (CNY Mn) | 3,497.9 | 1,325.9 | 636.4 | 1,566.1 | 51.7 |
Borrowings due after one year (CNY Mn) | 1,020.1 | 593.7 | 1,111.7 | 201.2 | 77.4 |
Net debt (CNY Mn) | 3,834.1 | 1,193.7 | 844.0 | 1,106.2 | -177.4 |
Goodwill (CNY Mn) | — | 0 | 38.6 | — | — |
Other intangible assets (CNY Mn) | — | 0 | 13.8 | — | — |
Properties for sale (CNY Mn) | — | 9,213.5 | 7,422.0 | — | — |
Investment properties (CNY Mn) | — | 1,230.6 | 1,387.3 | — | — |
Net current assets (CNY Mn) | — | 1,689.6 | 2,015.5 | — | — |
Contingent mortgage guarantees (CNY Mn) | 3,136.7 | 1,339.7 | 915.3 | 850.2 | 0 |
Capital commitments PUD (CNY Mn) | 1,829.0 | 2,133.2 | 1,655.9 | 766.0 | 0 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow aggregator (CNY Mn) | -528.7 | -108.0 | -126.8 | -31.0 | — |
Capital expenditure aggregator (CNY Mn) | -7.1 | -7.5 | -11.3 | -17.2 | — |
Free cash flow aggregator (CNY Mn) | -535.8 | -115.5 | -138.1 | -48.2 | — |
Dividends paid (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average total equity (%) | — | 41.4 | -29.7 | -173.5 | 151.4 |
ROA on average total assets (%) | — | 6.6 | -6.2 | -23.2 | 23.4 |
Current ratio (x) | 1.19 | 1.18 | 1.26 | 0.88 | 1.33 |
Gearing total borrowings to total equity (x) | 1.89 | 0.76 | 0.70 | 4.45 | 0.07 |
Interest coverage PBT plus finance costs (x) | 1.44 | 7.0 | -5.6 | -18.4 | 21.9 |
Asset turnover (x) | — | 0.33 | 0.12 | 0.15 | 0.22 |
Revenue by Region
| Region | FY2023 | FY2024 |
|---|---|---|
Mainland China revenue (CNY Mn) | 5,174.9 | 1,431.8 |
Singapore revenue (CNY Mn) | 0 | 9.1 |
Hong Kong revenue (CNY Mn) | 0 | 0 |
Segment Overview — Medical and pharmaceutical retail
| Segment | Mainland China (CNY Mn) | Singapore (CNY Mn) | Total (CNY Mn) |
|---|---|---|---|
Medical and pharmaceutical retail | 78.7 | 9.1 | 87.8 |
E-commerce and distribution | 621.4 | 0 | 621.4 |
Property development | 558.2 | 0 | 558.2 |
Property investment and management | 173.6 | 0 | 173.6 |
Total | 1,431.8 | 9.1 | 1,441.0 |
Locations
| Location | FY2023 | FY2024 |
|---|---|---|
Mainland China non-current assets (CNY Mn) | 1,498.8 | 1,626.0 |
Hong Kong non-current assets (CNY Mn) | 0.2 | 1.3 |
Singapore non-current assets (CNY Mn) | 0 | 2.0 |
Share Price History
| Date | Price (HKD) | Note |
|---|---|---|
29 Dec 2023 | 0.40 (equivalent) | Pre-consolidation HK$0.10 × 4 (option grant date) |
2 Sep 2022 | 0.476 (equivalent) | Pre-consolidation HK$0.119 × 4 (option grant date) |
52-week low (as of mid-2026) | 0.141 | Tiger Brokers quote page |
18 Jun 2026 | 0.41 | Day after profit alert (+15.5%) |
22 Jun 2026 | 0.485 | Peak close in run-up (52-week high approx. 0.50) |
17 Jul 2026 | 0.315 | Post-results fade |
31 Jul 2026 | 0.345 | stockanalysis |
9 Oct 2026 | 0.285 | Latest close retrieved (etnet) |
Valuation Snapshot
| Multiple | Value | Basis / caveat |
|---|---|---|
Market capitalisation | Approx. HK$780m | 2,737.4m shares × HK$0.285 |
Trailing P/E | Approx. 0.4x | EPS RMB0.6515; not meaningful, driven by one-off disposal gains |
P/B (owners' equity) | Approx. 1.2x | Owners' equity RMB589.7m (approx. HK$640m) |
EV | Approx. RMB1.0bn (approx. HK$1.1bn) | Market cap + debt RMB129.1m + NCI RMB1,185.5m - cash RMB306.5m |
EV/Sales | Approx. 0.65x | FY2026 revenue RMB1,551.5m |
Debt Maturity Profile
| Maturity bucket | Amount (CNY Mn) |
|---|---|
Within 1 year | 51.7 |
1–2 years | 0 |
2–3 years | 77.4 |
Total | 129.1 |
Analyst Conclusions
Management guidance
No quantitative guidance. Management's qualitative outlook for FY2027:
-
e-commerce: continued growth and an expanded health-product range;
-
pharma: recovery via digital channels;
-
property: orderly asset disposals;
-
asset management: prudent development.
The interim results for the six months to 30 September 2026 are due by the end of November 2026.
Consensus
None available (no coverage).
Bull case
-
Clean slate with net cash. Gearing of 0.07x, net cash of RMB177m and no guarantees or PUD commitments give management freedom to redeploy capital for the first time since 2020.
-
E-commerce operating leverage. If revenue keeps compounding at about 30% (FY2026: +31.5%) and own-brand health products lift margins from 3% towards 5–6%, the segment could plausibly earn RMB50–70m. That would be a meaningful figure against a market capitalisation of about HK$780m. This is illustrative, not a forecast.
-
Bargain acquisitions. The Tanzanian targets' reported net assets (about RMB448m) far exceed their US$6.59m price. If those assets are bona fide and income-producing, completion could add book value well above cost and create a new earnings stream.
Bear case
-
No earnings engine. The group has posted operating losses in five consecutive reporting periods, and the FY2026 "profit" came entirely from deconsolidation. Pharma is losing money and shrinking, and e-commerce margins are too thin to cover head-office costs.
-
New liabilities against a small equity base. The September 2026 SPC judgment (RMB187m plus about 6.5+ years of interest) could consume a large share of the RMB306.5m cash balance and roughly a third or more of owners' equity, depending on accounting treatment and enforcement.
-
Governance and capital-allocation risk. Insider-controlled ownership, recurring counterparties (Suzhou Aoze), an abandoned JV and an unrelated pivot into African aluminium and lead recycling do not show disciplined capital allocation. The 2021 misappropriation episode sets a low trust baseline.
Catalysts and monitorables (next 12 months)
| Item | Expected timing | What to watch |
|---|---|---|
| H1 FY2027 interim results (to 30 Sep 2026) | By end-Nov 2026 | Accounting for the SPC judgment; e-commerce growth; pharma losses; cash level |
| Completion of the Tanzanian acquisitions | Within approx. 3 months of 29 Jul 2026 (approx. late Oct 2026) | Purchase-price allocation; any bargain-purchase gain; target audited accounts |
| Enforcement or settlement of the Ping An Huitong judgment | Q4 2026–2027 | Cash outflow quantum; revival of the RMB24.36m follow-on claim |
| Board changes after Hou Ruilin's exit | Ongoing | Shareholding changes in SFO disclosures; any change in insider control |
| Remaining property inventory sell-down | Ongoing | ASP trend versus RMB5,085/sqm; investment-property fair values |
| Pharma store count and clinic expansion | Interim and annual reports | Stabilisation versus further closures |
| Partnership (On Tai) outcomes | Ongoing | Any claw-back, top-up or recourse to the group as subordinated LP |
| FY2027 annual results | Jun 2027 | First clean year without development operations |
Concluding analyst verdict
Peking University Resources has done one important thing well. It has escaped the property-development liabilities that pushed its owners' equity into deficit twice in four years.
The August 2025 partnership did several things at once:
-
deconsolidated defaulted loans, mortgage guarantees and the legacy Huzi guarantee provisions;
-
produced a RMB1.65 billion accounting profit;
-
cut borrowings from RMB1.77 billion to RMB129 million.
On balance-sheet risk alone, FY2026 marks a true inflection.
What remains, however, is not yet a business with demonstrated earnings power. The e-commerce segment is growing quickly but earns 3 cents per yuan of sales. The Ye Kai Tai pharmacy chain, bought in 2023 as the strategic growth pillar, has lost 18 stores in two years, swung to a loss and had its goodwill written off. On the aggregator's definition, consolidated operating income has been negative in every period for five years. Meanwhile the September 2026 Supreme People's Court ruling has added a nine-figure liability. Against roughly RMB590 million of owners' equity and RMB307 million of cash, it is material.
Capital allocation since the clean-up has not built confidence:
-
a metals-trading JV announced and abandoned within four months;
-
a Dubai digital-health venture;
-
an AI partnership;
-
two Tanzanian industrial acquisitions at prices far below reported book value.
The last of these may prove value-accretive, but it raises legitimate questions about asset quality, related parties and strategic fit. Insider concentration of about 45% across executive directors at the last disclosure, and the 2021 misappropriation history, warrant a governance discount.
At about HK$0.285 the market already treats the FY2026 profit as non-recurring. The shares trade near 1.2x owners' book value and about 0.65x EV/sales, with no dividend and no coverage. We regard the equity as a high-risk special situation rather than an investable operating story. Re-rating would require a clean H1 FY2027 that contains the SPC liability, sustained profitable e-commerce growth, pharma stabilisation and transparent integration of the Tanzanian assets. Until then, the risk/reward is asymmetric to the downside.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | First appointed | Committees | Notes |
|---|---|---|---|---|
Mr Wong Kai Ho (黃啓豪) | Chairman, Executive Director | 2021 | Nomination (Chair), Remuneration | Largest shareholder (22.32% as of May 2024); company secretary until 11 Jul 2022; holds 2.575m options |
Mr Huang Zhuguang (黃柱光) | Executive Director | 2021 | — | Authorised representative; 11.66% with connected persons (May 2024) |
Mr Xia Ding (夏丁) | Executive Director; Co-CEO; COO | 30 Aug 2024 | — | President of several subsidiaries; holds 5.75m options |
Mr Hou Ruilin (侯瑞林) | Executive Director | 2023 | — | Resigned 14 Sep 2026; 10.61% holder (May 2024) |
Ms Xiong Yan (熊妍) | Executive Director | Sep 2026 | — | — |
Mr Chin Chi Ho, Stanley (錢志浩) | INED | 2021 | Audit (Chair), Remuneration | Financial expertise |
Ms Xu Nan (徐楠) | INED | 30 Aug 2024 | Audit, Nomination | Only female director |
Prof Cheung Ka Yue (張嘉裕) | INED | 30 Sep 2024 | Remuneration (Chair), Audit, Nomination | — |
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Mr Shi Lei (石磊) | Co-Chief Executive Officer | CEO since at least FY2023 |
Mr Xia Ding | Co-CEO and COO | See above |
Mr Jiang Xiaoping (蔣小平) | Deputy CEO; president of several subsidiaries | 5.5m options outstanding |
Ms Zhang Jiabo (張佳博) | Company Secretary | Appointed 30 Jan 2026 (replaced Ms Leung Mei King) |
CFO | Not publicly disclosed in retrieved material | — |
Governance Detail
| Band (MYR Bn) | Number |
|---|---|
0 – 1,000,000 | 1 |
2,000,000 – 3,000,000 | 1 |
Major Shareholders
| Holder | Shares | % of issued |
|---|---|---|
Wong Kai Ho | 611,104,039 | 22.32 |
Huang Zhuguang and connected persons | 319,203,743 | 11.66 |
Hou Ruilin | 290,307,782 | 10.61 |
Wu Wenbo (伍文波) | 175,000,000 | 6.39 |
Chen Mengyi (陳夢怡) | 175,000,000 | 6.39 |
Top-5 total | 1,570,615,564 | 57.37 |
Governance Detail by Participant
| Participant | Shares (m) | % |
|---|---|---|
格理昂證券有限公司 | 619 | 22.60 |
Everbright Securities Investment Services (HK) | 339 | 12.39 |
UOB Kay Hian (HK) | 112 | 4.11 |
HSBC | 95.7 | 3.50 |
Maybank Securities (HK) | 53.7 | 1.96 |
Guotai Junan Securities (HK) | 52.4 | 1.91 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs PKU Resources |
|---|---|---|
Pharma retail (national chains) | Dashenlin (大參林) | National-scale chain; orders of magnitude larger |
Pharma retail | Yifeng Pharmacy (益豐藥房) | Same |
Pharma retail | LBX Pharmacy (老百姓大藥房) | Same |
Pharma retail | Yixintang (一心堂) | Same |
Pharma retail / TCM heritage brands | Beijing Tong Ren Tang (北京同仁堂) | Time-honoured TCM peer cited by the company |
Pharma retail / TCM heritage brands | Hangzhou Huqingyutang (胡慶餘堂) | Same |
Pharma retail / TCM heritage brands | Guangzhou Chan Li Chai (陳李濟) | Same |
Pharma retail (regional, Hubei) | Jointown (九州通) retail operations and local Wuhan independents | Local share competition (no data) |
E-commerce TP / brand operation | Baozun (寶尊電商) | Largest listed brand e-commerce partner; fee-based plus distribution |
E-commerce TP / brand operation | Ruoyuchen (若羽臣) | Brand operation plus own brands |
E-commerce TP / brand operation | Lily & Beauty (麗人麗妝) | Beauty-focused TP |
Distribution (legacy IT) | Digital China (神州數碼) | Largest China IT distributor; PKU exited traditional IT distribution |
Property (run-off) | Numerous PRC developers | Irrelevant to forward thesis |
Peer Comparison FY2026
| Company | Latest FY revenue | Revenue growth | Margin indicator |
|---|---|---|---|
PKU Resources (FY2026, MYR Bn) | 1.55bn | -4.1% | Gross 7.4%; operating approx. -11.9% (aggregator) |
Dashenlin (FY2024, MYR Bn) | Approx. 24–25bn | — | — |
Yifeng Pharmacy (FY2024, MYR Bn) | Approx. 24bn | — | — |
Baozun (FY2024, MYR Bn) | Approx. 9bn+ | — | — |
Recent Developments
All material items found are included.



